Search research articles
Contact Us
Filters
Showing results (131-140 of 274) with videos related to
Page
of 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
Casey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, et al.
The British Journal of Radiology
|
June 15, 2017
Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease
Amar U Kishan, Justin C Voog, Jonathan Wiseman, et al.
Practical Radiation Oncology
|
May 3, 2017
Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation
Brent Rose, Devarati Mitra, Theodore S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2008
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H Kulke, Heinz-Josef Lenz, Neal J Meropol, et al.
American Journal of Clinical Oncology
|
October 15, 2016
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma
Florence K Keane, Jennifer Y Wo, Cristina R Ferrone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
Eileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Cancer
|
March 14, 2020
Symptom burden in patients with cancer who are experiencing unplanned hospitalization
Richard A Newcomb, Ryan D Nipp, Lauren P Waldman, et al.
Cancer Chemotherapy and Pharmacology
|
June 21, 2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
Andrew X Zhu, Jeffrey W Clark, David P Ryan, et al.
Cancer
|
November 1, 2006
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
David P Ryan, Bert H O'Neil, Jeffrey G Supko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
Shuji Ogino, Jeffrey A Meyerhardt, Mami Cantor, et al.
Page
of 28
Search research articles
Search
Showing results (131-140 of 274) with videos related to
Sort By:
Page
of 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
Casey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, et al.
The British Journal of Radiology
|
June 15, 2017
Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease
Amar U Kishan, Justin C Voog, Jonathan Wiseman, et al.
Practical Radiation Oncology
|
May 3, 2017
Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation
Brent Rose, Devarati Mitra, Theodore S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2008
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H Kulke, Heinz-Josef Lenz, Neal J Meropol, et al.
American Journal of Clinical Oncology
|
October 15, 2016
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma
Florence K Keane, Jennifer Y Wo, Cristina R Ferrone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
Eileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Cancer
|
March 14, 2020
Symptom burden in patients with cancer who are experiencing unplanned hospitalization
Richard A Newcomb, Ryan D Nipp, Lauren P Waldman, et al.
Cancer Chemotherapy and Pharmacology
|
June 21, 2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
Andrew X Zhu, Jeffrey W Clark, David P Ryan, et al.
Cancer
|
November 1, 2006
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
David P Ryan, Bert H O'Neil, Jeffrey G Supko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
Shuji Ogino, Jeffrey A Meyerhardt, Mami Cantor, et al.
Page
of 28